The Effect of the Modified Glasgow Prognostic Score and Neutrophil/Lymphocyte Ratio on Prognosis in Stage 4 Pancreatic Cancer
Ahmet Ozveren11Department of Medical Oncology, Private Izmir Kent Hospital, Izmir, Türkiye
Objectives: To demonstrate that the neutrophil/lymphocyte ratio (NLR) and modified Glasgow Prognostic Score (mGPS) are negative prognostic factors for overall survival and mGPS is a more sensitive marker in patients diagnosed with stage 4 pancreatic cancer (PC). Methods: A total of 68 patients with stage 4 PC were included in the study. Clinical and laboratory data were collected and evaluated in the form of retrospective file scanning. Analysis was performed using the SPSS database. Results: The median age at diagnosis was 67 years, the median progression-free survival (PFS) was 5.2 months, and the median overall survival (OS) was 11.1 months. OS was 18.1 months in patients with low NLR and 10.4 months in patients with high NLR (*p=0.013). OS was 21.3 months in patients with an mGPS of 0, 10.3 months in patients with an mGPS of 1, and 5.5 months in patients with an mGPS of 2 (*p=0.001). Conclusion: Eastern Cooperative Oncology Group (ECOG) performance status score, NLR, and mGPS are unfavorable prognostic factors for OS in stage 4 PC. mGPS is a more sensitive prognostic factor than both ECOG performance status score and NLR. Keywords: Stage 4 pancreatic cancer, neutrophil/lymphocyte ratio, modified Glasgow prognostic score
Cite This Article
Ozveren A. The Effect of the Modified Glasgow Prognostic Score and Neutrophil/Lymphocyte Ratio on Prognosis in Stage 4 Pancreatic Cancer. EJMI. 2023; 7(2): 137-140
Corresponding Author: Ahmet Ozveren